Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors

Regina Rendas-Baum, Gene V Wallenstein, Tamas Koncz, Mark Kosinski, Min Yang, John Bradley, Samuel H Zwillich

Abstract

Introduction: The long-term treatment of rheumatoid arthritis (RA) most often involves a sequence of different therapies. The response to therapy, disease progression and detailed knowledge of the role of different therapies along treatment pathways are key aspects to help physicians identify the best treatment strategy. Thus, understanding the effectiveness of different therapeutic sequences is of particular importance in the evaluation of long-term RA treatment strategies. The objective of this study was to systematically review and quantitatively evaluate the relationship between the clinical response to biologic treatments and the number of previous treatments with tumor necrosis factor α (TNF-α) inhibitors.

Methods: A systematic search was undertaken to identify published, peer-reviewed articles that reported clinical outcomes of biologic treatment among RA patients with an inadequate response to TNF-α inhibitors. Data were systematically abstracted. Efficacy rates were estimated for groups of patients who differed in the number of prior TNF-α inhibitors used. End points included American College of Rheumatology (ACR)-, European League Against Rheumatism (EULAR)- and Disease Activity Score 28 (DAS28)-based response criteria.

Results: The literature search identified 41 publications, of which 28 reported biologic treatment outcomes for RA patients with prior exposure to TNF-α inhibitors. Seven publications reported outcomes obtained in randomized clinical trials, while the remaining consisted of observational studies. The likelihood of responding to a subsequent biologic treatment decreased as the number of previous treatments with TNF-α inhibitors increased for six of the seven response criteria examined.

Conclusions: For patients with prior exposure to TNF-α inhibitors, the likelihood of response to subsequent treatment with biologic agents declines with the increasing number of previous treatments with TNF-α inhibitors.

Introduction

The chronic nature of rheumatoid arthritis (RA) and its progression over time in spite of a variety of treatment options implies that long-term treatment will most often involve a sequence of therapies. The optimal therapeutic sequence strategy will be determined largely by the patient’s response to therapy and by disease progression, as well as detailed knowledge of the role of different therapies along treatment pathways. Thus, understanding the effectiveness of different therapeutic sequences is of particular importance in the evaluation of long-term RA treatment strategies.

There are three main drug classes commonly used in the treatment of RA: nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs). Several studies [1-3] have provided evidence that early treatment with DMARDs results in superior clinical and radiological
outcomes. Two main classes of DMARDs are available for the treatment of RA: synthetic DMARDs and biologic DMARDs. Oral administration, lower cost and greater prescriber familiarity support the use of synthetic DMARDs as a first-line strategy. Biologic DMARDs, most often in combination with synthetic DMARDs, are generally reserved for the treatment of patients with moderate to severe RA who have had an inadequate response or have developed toxicities to synthetic DMARDs [4].

A review of 16 clinical practice guidelines and 20 consensus statements on RA treatment revealed that while tumor necrosis factor (TNF)-α inhibitors were consistently recommended for patients with active RA and a history of inadequate response to synthetic DMARDs [5], the management of patients who stopped an initial TNF-α treatment because of lack of initial response, loss of initial response or side effects continues to be the subject of much debate, and guidelines for patient management are nearly absent. Despite the lack of guidelines, it is estimated that upon encountering an inadequate response or side effects with a TNF-α inhibitor, over 90% of rheumatologists in the United States switch patients to a different TNF-α inhibitor [6].

Estimates of efficacy rates of TNF-α inhibitors may depend on a number of factors, including patient characteristics, such as disease duration, prognostic factors, number of previously failed DMARDs and disease activity, as well as the dose of TNF-α inhibitor and the designs of the studies from which they were obtained. Despite some variation attributable to these factors, estimates derived from randomized, controlled trials (RCTs) suggest that between 40% and 50% [7] of RA patients treated for at least 6 months with one of the three first-generation TNF-α inhibitors (etanercept, adalimumab and infliximab) failed to achieve the American College of Rheumatology 50% (ACR50) improvement criteria [8], while the results from a large, registry-based study [9] indicated that over 70% of these patients fail to achieve Disease Activity Score 28 joint count (DAS28)-defined "remission" (DAS28 <2.6).

Although the efficacy of TNF-α inhibitors in patients who are naïve to biologic treatment has been evaluated in multiple studies [10–12], evaluating the efficacy of these drugs in patients who have already experienced an inadequate response to a TNF-α inhibitor poses greater methodological challenges. One key aspect of evaluating the efficacy of sequential TNF-α therapy is to determine whether the probability of responding to a TNF-α inhibitor depends on the results of prior treatment with these drugs. Early evidence from small observational studies suggested that a significant proportion of patients who had an inadequate response to an initial TNF-α inhibitor benefited from subsequent treatment with an alternative TNF-α inhibitor [13-15]. Recent data derived from registries, however, have suggested that the response rates of patients switching to a second or third TNF-α inhibitor are often lower than the response rates of patients to the first TNF-α inhibitor [16,17]. Moreover, the broader question whether it is more effective to switch to another mechanism of action or to use a second TNF-α inhibitor after the patient has had an inadequate response to a first one has not been formally addressed.

In the present study, several biologic treatment options currently available to RA patients with an inadequate response to an initial TNF-α inhibitor were evaluated using evidence gathered from published reports. We undertook a systematic review of published, peer-reviewed studies that reported clinical outcomes of biologic treatment among this group of patients. Our study expands on previously published reviews in two ways: first, information on efficacy rates of newer biologics with different mechanisms of action among patients with an inadequate response to TNF-α inhibitors was also included and results were examined separately for TNF-α inhibitors and other biologic DMARDs; second, a quantitatively based evaluation of the relationship between response to biologic treatment and the number of failed TNF-α inhibitors was undertaken by summarizing the results of published studies. Within the limitations of the existing data, potential effect-modifying factors, such as study design and treatment duration, were also examined. A secondary objective of this study was to determine whether clinical response to a subsequent TNF-α differed by reason for discontinuation.

Materials and methods

Search strategy

A search was carried out in the PubMed database using each of the following search terms as keywords or text words: “golimumab,” “adalimumab,” “infliximab,” “etanercept,” “abatacept,” “rituximab,” “anakinra,” “tocilizumab,” “certolizumab pegol,” “anti-TNF,” “TNF-antagonist,” “TNF-inhibitor,” “biologic” in combination with “switch” or “sequential therapy” or “therapy interchange,” and “rheumatoid arthritis.” Brand names of biologics were also used for each of the drugs cited above. The search was restricted to the English language and had an end date of 31 December 2009. The reference lists of selected review publications were further examined to identify any studies that were not captured by our search.

Articles were included in the analyses if the publications reported any quantitative clinical and/or health-related quality of life outcomes for RA patients previously failing one or more TNF-α inhibitors. Studies with fewer than 20 participants were excluded.
**Database development**

The characteristics of each study were recorded, including the study design and major findings. Disease duration, age, sex distribution, duration of treatment, duration of washout period (if reported), concomitant use of methotrexate (percentage of patients within the group), dose of biologic drug and all clinical and quality-of-life measures were recorded for each group of patients on the basis of the total number of biologics that had been tried at the time the outcome was measured. Studies differed with respect to the way in which washout periods were reported. For this study, washout periods were noted in the following manner: (1) if the mean or median was reported (the median was preferred if both were reported) for the time elapsed between the last dose of prior treatment until the first dose of subsequent treatment, this value was recorded; and (2) if no summary statistic for the washout period was reported, the minimum washout period required per study protocol was recorded. For RCTs in which different doses of biologic DMARDs were administered, efficacy estimates based on all study arms were included. The sensitivity of the results to this parameter was assessed in the analyses.

Some studies reported outcomes of multiple switches for the same group of patients, so the same group of patients might have contributed to more than one combination of outcome measures and number of biologics tried. A few studies did not report results disaggregated by the actual number of prior TNF-α inhibitors tried and reported only the results of the biologic under study for subjects with an inadequate response to at least one TNF-α inhibitor (in these cases, the number of biologics under study was recorded as 2+).

Several studies did not allow for within-study evaluation of differences in clinical or health-related quality-of-life outcomes across groups differing in the number of previous TNF-α inhibitors used. For these studies, the results of various outcome measures were reported for a single comparison group.

**Efficacy estimates**

All estimates were evaluated for each combination of measure and biologic number (that is, first, second, and so on), as well as for relevant subgroups. All estimates were evaluated as weighted averages using sample size as the weight in the following formula:

$$Rate_{j} = \sum_{i=1}^{n} \left( \frac{SS_{i} \cdot Rate_{i}}{N} \right)$$

where $Rate_{j}$ represents the average response rate for measure $j$, $i$ indexes the group, $n_{i}$ is the sample size for the $i$th group and $N$ is the combined sample size of all groups.

The main focus was on estimating the efficacy rate on the basis of each of the main response criteria reported in the studies identified by our review across the number of previously failed biologics. Nevertheless, some of the publications included in the current study also reported efficacy rates associated with a first trial of TNF-α treatment. Weighted estimates were also evaluated for this group of patients and served as a further check of how the values obtained in the current study compared to published rates. Estimates were also evaluated within the following subgroups: type of study (observational study versus RCT), duration of follow-up (<6 months versus 6 months or longer), type of biologic (TNF-α inhibitor versus other) and reason for discontinuation (lack of response, loss of response or intolerance).

**Results**

**Characteristics of biologic treatments for RA**

Table 1 presents a brief overview of current biologic DMARDs, including their brand names, dates of approval by the Food and Drug Administration for the treatment of RA, mode of action and schedule of administration.

**Study characteristics**

On the basis of an abstract review, 41 publications were identified as potentially reporting clinical outcomes of patients who had switched to a second or subsequent biologic DMARD. Upon full review of the 41 publications, 28 were included in the study. The remaining 13 publications [16,18-29] were excluded for one or more of the following reasons: (1) the information reported was not relevant to the objective of our analysis, (2) quantitative results could not be extracted from the publication, and/or (3) the study sample did not include patients with an inadequate response to one or more TNF-α inhibitors. Our search did not uncover any information that pertained to the effect of certolizumab pegol or anakinra for the treatment of patients with an inadequate response to TNF-α inhibitors. Two [30,31] of the 28 publications included reports that contained analyses of patients with conditions other than RA. The percentage of RA patients was 80% and 95% across these two studies. Both studies were small, with a combined sample size of 93 patients. Of the 26 remaining publications, five were randomized trials (one was not placebo-controlled). One publication [32] reported results associated with different doses of tocilizumab (4 and 8 mg).

Key characteristics of the 28 [14,15,17,29-53] selected publications, including a brief description of their key
findings, are presented as supplementary material (Additional file 1). The studies used in specific subgroup analyses are also identified.

Outcome measures
The types of outcome measures reported across the 28 publications differed considerably. The most commonly reported efficacy measures were ACR-, European League Against Rheumatism (EULAR)- and DAS28-based response criteria. Health Assessment Questionnaire (HAQ) scores were also commonly reported, but in different ways across studies. In some cases, the publication reported mean values at baseline and posttreatment, while in other cases only the absolute or percentage change from baseline were reported. ACR-based response criteria were reported for all seven drugs, while most of the other measures were available for three or four drugs. Information on response rates across groups based on the number of previous TNF-α inhibitor treatments differed substantially by drug. The efficacy of etanercept, for example, although available across a number of response criteria, was explicitly reported only for patients with one previous TNF-α inhibitor treatment trial. In addition, some studies did not report the actual drug used and presented results aggregated over the three first-generation TNF-α inhibitors (adalimumab, etanercept and infliximab). On the basis of the greatest availability of data and relevance as markers of clinical response, the following efficacy measures were selected: ACR20, ACR50 and ACR70 rates; DAS28 low disease activity rates (DAS28 ≤3.2) [54]; DAS28 remission rates (DAS28 <2.6) [55]; and EULAR-based rates of moderate and good responses [56].

Efficacy estimates based on number of previous TNF-α inhibitors
Average response rates by number of TNF-α inhibitors are shown in Figure 1 for ACR-, EULAR- and DAS28-based response criteria. The bar graphs in Figure 1 show that for six of the seven indicators examined, the likelihood of patient response to a subsequent biologic treatment decreased slightly in patients with a greater number of previous treatments with TNF-α inhibitors.

The main exception to the trend of decreasing likelihood of response was the association between EULAR moderate response rates and the number of previous TNF-α inhibitors. Upon close examination, the study characteristics do not appear to explain this difference (see Table 2). From among the 10 studies used to derive EULAR response rates, only three [33,36,45] reported these rates on the basis of the number of previous TNF-α inhibitors. For these three studies, within-study differences in good EULAR response rates consistently declined with increasing number of previous TNF-α inhibitors.
Figure 1 Percentage of patients achieving a response according to biologic treatment number. Bar graphs showing the percentage of patients achieving a response to any biologic disease-modifying antirheumatic drug (DMARD) according to criteria commonly used in rheumatoid arthritis (RA) patients, separated by number of biologic DMARDs to which the patients were exposed. With regard to the ACR categories, ACR20 means a 20% improvement in tender or swollen joint counts as well as 20% improvement in at least three of the following five criteria: patient assessment, physician assessment, erythrocyte sedimentation rate, pain scale and functional questionnaire. The ACR50 and ACR70 categories adhere to the same criteria, but for 50% and 70% improvement, respectively. ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; DAS28, Disease Activity Score 28 joint count.
inhibitors. However, for the same three studies, within-study differences in moderate EULAR response rates by number of previous TNF-α inhibitors did not show a clear trend. For example, on the basis of the results of the ReAct open-label trial [36], good EULAR response rates were 35%, 25% and 11% for the first, second and third TNF-α inhibitors administered, respectively, while for moderate EULAR responses, these rates were 49%, 53% and 51%, respectively. Thus, even within the same study, the relationship between moderate EULAR response rates and the number of previous TNF-α inhibitors administered was different from the relationship between good EULAR response rates and the number of previous TNF-α inhibitors used.

Table 2 Information used to evaluate the proportion of patients achieving a response according to common criteria used in RA studiesa

| Measure | Number of biologics used | Number of patients | Estimated response rate, % | Specific biologics used to derive response rate | Treatment duration range, months | Mean age range, yr | Mean RA duration range, yr | Reference sources |
|---------|--------------------------|--------------------|---------------------------|-----------------------------------------------|-------------------------------|------------------|-----------------------------|------------------|
| ACR20   | 1                        | 5,762              | 70.0                      | ADA                                           | 6 to 12                       | 53 to 56         | 11 to 16                    | [30,36,51]       |
|         | 2                        | 1,911              | 52.7                      | ADA, ETN, GLM, IFX, TCZ, TNF_3             | 3 to 12                       | 45 to 57         | 9 to 17                     | [14,15,17,30,32,34,36,37,51-53] |
|         | 2+                       | 772                | 53.3                      | ADA, RTX                                      | 6 to 12                       | 52 to 53         | 12                          | [39,41,42]       |
|         | 3                        | 339                | 46.0                      | ADA, GLM, TCZ, TNF_3                        | 3 to 6                        | 51 to 58         | 11 to 15                    | [17,32,36,52]    |
|         | 4                        | 46                 | 31.9                      | GLM, TCZ                                      | 4 to 6                        | 51 to 54         | 11 to 13                    | [32,52]          |
| ACR50   | 1                        | 5,736              | 41.1                      | ADA                                           | 3 to 12                       | 54 to 56         | 11 to 16                    | [36,51]          |
|         | 2                        | 1,699              | 30.1                      | ETN, TCZ, TNF_3, ADA, IFX                   | 3 to 12                       | 45 to 57         | 9 to 17                     | [14,15,17,32,34,36,37,51] |
|         | 2+                       | 1,078              | 23.5                      | GLM, ADA, RTX                                | 4 to 12                       | 52 to 55         | 9 to 12                     | [39,41,42,52]    |
|         | 3                        | 268                | 24.4                      | TCZ, TNF_3, ADA                              | 3 to 6                        | 51 to 58         | 11 to 15                    | [17,32,36]       |
|         | 4                        | 44                 | 20.5                      | TCZ                                           | 6                             | 51 to 54         | 11 to 13                    | [32]             |
| ACR70   | 1                        | 5,736              | 19.1                      | ADA                                           | 3 to 12                       | 54 to 56         | 11 to 16                    | [36,51]          |
|         | 2                        | 1,686              | 12.0                      | ADA, ETN, TCZ, TNF_3                        | 3 to 12                       | 49 to 57         | 8 to 17                     | [5,17,32,34,36,37,47,51,53] |
|         | 2+                       | 1,078              | 11.9                      | ADA, TCZ, RTX                                | 4 to 12                       | 52 to 55         | 9 to 12                     | [39,41,42,52]    |
|         | 3                        | 268                | 12.7                      | TCZ, TNF_3                                   | 3 to 6                        | 51 to 58         | 11 to 15                    | [17,32,36]       |
|         | 4                        | 44                 | 4.5                       | TCZ                                           | 6                             | 51 to 54         | 11 to 13                    | [32]             |
| DAS28 <2.6 | 1                      | 5,711              | 21.0                      | ADA                                           | 3                             | 54                | 11                          | [36]             |
|         | 2                        | 1,604              | 14.9                      | ADA, TNF_3                                    | 3 to 6                        | 53 to 56         | 12 to 14                    | [17,29,36]       |
|         | 2+                       | 331                | 19.2                      | TCZ                                           | 6                             | 51 to 54         | 11 to 13                    | [36]             |
|         | 3                        | 496                | 10.2                      | ADA, TNF_3                                    | 3 to 6                        | 52 to 58         | 12 to 15                    | [17,29,36]       |
|         | 4                        | 200                | 6.5                       | ADA                                           | 6                             | 56                | -                           | [29]             |
| DAS28 <3.2 | 2                      | 1,219              | 22.7                      | ADA, TNF_3, TNF_N2                          | 3 to 6                        | 55 to 56         | 8 to 14                     | [17,29,40]       |
|         | 2+                       | 331                | 33.7                      | TCZ                                           | 6                             | 51 to 54         | 11 to 13                    | [32]             |
|         | 3                        | 376                | 21.6                      | ADA, TNF_3                                    | 3 to 6                        | 56 to 58         | 15                          | [17,29]          |
|         | 4                        | 200                | 15.0                      | ADA                                           | 6                             | 56                | -                           | [29]             |
| EULAR moderate | 1                   | 6,494              | 480.0                    | ADA, TNF                                      | 3 to 8                        | 54 to 57         | 8 to 11                     | [33,36,45]      |
|         | 2                        | 1,854              | 44.4                      | ADA, ETN, TNF_3                               | 3 to 12                       | 53 to 61         | 8 to 13                     | [35-38,43,45]    |
|         | 2+                       | 324                | 49.7                      | TNF, RTX                                      | 6 to 9                        | 52                | 12                          | [33,39]         |
|         | 3                        | 120                | 51.0                      | ADA                                           | 3                             | 52                | 12                          | [36]             |
| EULAR good | 1                      | 6,494              | 340.0                    | ADA, TNF                                      | 3 to 8                        | 54 to 57         | 8 to 11                     | [33,36,45]      |
|         | 2                        | 2,232              | 194.0                     | ADA, ETN, TNF_3                               | 3 to 12                       | 53 to 61         | 8 to 14                     | [17,36-38,43,45,53] |
|         | 2+                       | 324                | 15.3                      | TNF_N2, RTX                                   | 6 to 9                        | 52                | 12                          | [33,45]         |
|         | 3                        | 156                | 10.5                      | ADA, TNF_3                                    | 3                             | 52 to 58         | 12 to 15                    | [17,36]         |

aRA, rheumatoid arthritis; ACR, American College of Rheumatology; DAS28, Disease Activity Score 28 joint count; EULAR, European League Against Rheumatism. ABA, abatacept; ADA, adalimumab; ANA, anakinra; ETN, etanercept; GLM, golimumab; IFX, infliximab; RTX, rituximab; TNF, i.th TNF-α inhibitor; TCZ, tocilizumab.

ACR20 means a 20% improvement in tender or swollen joint counts as well as 20% improvement in at least three of the following five criteria: patient assessment, physician assessment, erythrocyte sedimentation rate, pain scale and functional questionnaire. The ACR50 and ACR70 categories adhere to the same criteria, but for 50% and 70% improvement, respectively.
Although less pronounced, a second departure from
the general trend was the fact that the proportion of
patients achieving low disease activity (DAS28 <3.2) and
remission (DAS28 <2.6) was higher among patients in
whom one or more TNF-α inhibitors had previously
failed (bars labeled “2+” in Figure 1) than for patients
with a single failed TNF-α treatment trial (bars labeled
“2” in Figure 1). The source of the 2+ group value was a
single RCT of tocilizumab [32] with a follow-up length
of 6 months, while the estimated response rates regard-
ing the second, third and fourth biologic treatments
were obtained from observational studies, several of
which had follow-up lengths of 3 months. In addition,
in one of these observational studies, DAS28 was evalu-
ated using C-reactive protein (CRP) level rather than
erythrocyte sedimentation rate (ESR) level. Although
CRP-based DAS28 scores are seen as a valid alternative
to the more commonly used ESR-based DAS28 scores,
there are reports that the former results in DAS28
values that are significantly lower [57,58], a finding that
agrees with the graphs shown in Figure 1.

Studies differed on a number of factors, such as type
of biologic, disease and treatment duration, which could
have a strong influence on these estimates (see Addi-
tional file 1, Table S1). To ascertain how the overall
estimates might have been affected by these factors,
stratified estimates were also evaluated.

Efficacy estimates stratified by type of biologic drug
(TNF-α inhibitors versus other biologics)

To examine whether the relationship between the num-
ber of previous TNF-α inhibitors and response rates
was different for TNF-α inhibitors when compared to
other types of biologic drugs (abatacept, rituximab or
tocilizumab), stratified response rates were evaluated for
these two main drug groups on the basis of ACR
response rates and DAS28 rates of low disease activity
and remission. It should be noted that the ACR
response rates for the “Other” biologics group shown in
Figure 2a are based on a single study of tocilizumab and
that the DAS-based rates are based on a single trial of
abatacept, limiting the value of the comparisons.

The results shown in Figure 2a suggest that the pre-
viously observed trend of declining response rates with
increasing number of prior TNF-α inhibitors used per-
sists for both TNF-α inhibitors and alternative biologic
drugs. However, the ACR20 response rates were 54%,
42% and 14% for the second, third and fourth TNF-α
inhibitors used, respectively, whereas for tociluzimab,
the ACR20 rates were 49%, 50% and 54%, respectively.
For TNF-α inhibitors, DAS28-based response rates for
the third TNF-α inhibitor were approximately 10 per-
centage points lower than the rates for the second TNF-
α inhibitor, but this decline was only about three
percentage points in the alternative biologic drugs group
(abatacept). Overall, a decline in response for the second
versus the third biologic drug was generally reported for
both TNF-α inhibitors and biologic DMARDs with
other modes of action. However, the decline in response
rates tended to be more pronounced for TNF-α
inhibitors.

Efficacy estimates stratified by study design

Several authors have reported that efficacy estimates of
TNF-α inhibitors in patients naïve to biologic treatment
are consistently different in RCTs and observational stu-
dies [59,60]. To determine whether the relationship
between response rates and previous exposure to TNF-
α inhibitors was preserved within the type of study
design, estimates were also obtained after stratifying
across two main types of studies: RCTs and observa-
tional studies. As shown in Figure 2b, the trend was
essentially the same across the two types of study
design, although response rates based on RCTs tended
to be lower than those of observational studies. We
examined the role of several factors which could have
potentially influenced this result by comparing the char-
acteristics of the nine observational studies
[15,17,30,34,36,37,47,53] with those of the three RCTs
[14,32,52] used to derive the ACR-based response rates
shown in Figure 2b. These comparisons revealed that
the two sets of studies were mostly similar with respect
to mean age (between 45 and 54 years of age for the
RCTs, and between 47 and 58 years of age for the
observational studies), disease duration (between 10 and
13 years for the RCTs, and between 9 and 17 years for
the observational studies) and time of efficacy assess-
ment. (Two (67%) of three RCTs and six (67%) of nine
observational studies reported efficacy at 3 and
4 months, while the remainder reported response rates
at 6 and 12 months.)

Further comparisons between RCTs and observa-
tional studies indicated that whereas all nine observa-
tional studies examined the efficacy of TNF-α inhibitors (adal-
mumab, etanercept or infliximab), the three RCTs
assessed the efficacy of golimumab, infliximab and toci-
Zumab. The infliximab RCT [14] used a small sample of
27 patients and hence contributed relatively little to the
weighted ACR response rates. The two other RCTs had
similar, much larger sample sizes, but golimumab
response rates were substantially lower than those of
tocilizumab. For example, the golimumab ACR20 rates
for patients previously exposed to either one or two
TNF-α inhibitors were both 38%, while the comparable
tocilizumab ACR20 response rates were 49% and 50%.
Studies which did not report response rates by the
actual number of previously attempted TNF-α inhibitors
were excluded from the comparison shown in Figure 2b.
Figure 2 Percentage of patients achieving a response by biologic type or study type and biologic number. (a) Bar graphs showing the percentage of patients achieving the American College of Rheumatology ACR20, ACR50 or ACR70 criteria (see description of these criteria in Figure 1 legend), as well as remission (DAS28 <2.6) or low disease activity (DAS28 ≤3.2) according to the number of biologic disease-modifying antirheumatic drugs (DMARDs) to which the patients were exposed and whether the drug switched to was a tumor necrosis factor (TNF)-α inhibitor or a different type of biologic agent (Other). ACR20, ACR50 and ACR70 rates are based on 8 mg/kg tocilizumab, and DAS28 <2.6 and DAS28 ≤3.2 are based on abatacept. (b) Bar graphs showing the percentage of patients achieving ACR-based improvement criteria according to the number of biologic DMARDs to which the patients were exposed and type of study design. RCT, randomized controlled trial; Observational, observational study.
(This group is shown as “2+” in Figure 1.) A total of three RCTs [39,41,52] were excluded. The estimated ACR20, ACR50 and ACR70 rates based on these trials were 53%, 24% and 12%, respectively (see also Table 2 for further details), which are within the ranges formed by the response rate estimates of the second and third TNF-α inhibitors.

Comparisons of the two sets of studies with respect to the reason for discontinuation were made difficult by inconsistent reporting. In the set of RCTs, only the golimumab trial [52] reported that lack of efficacy was a reason for discontinuation of TNF-α inhibitor therapy for 58% of study participants, while 53% of participants also stated reasons unrelated to efficacy. For the infliximab [14] and tocilizumab trials [32], the reasons for discontinuation were either absent or not clearly stated. Six of the nine observational studies included patients who had discontinued therapy with a TNF-α inhibitor for reasons other than inefficacy, with study percentages ranging between 12% (5 of 41 patients) and 100% (37 of 37 patients). For observational study ACR20 response rates, for example, we estimated that approximately one-fourth of the total sample (396 of 1,512 patients) had discontinued TNF-α inhibitor therapy for reasons other than lack of efficacy. Overall, differences in reporting made it impossible to assess whether the reason for discontinuation could have explained the lower response rates observed among RCTs.

**Efficacy estimates based on reason for discontinuation**

The association between response rates and reasons for discontinuation was evaluated by examining studies that reported clinical response rates to a second TNF-α inhibitor by reason for discontinuation of a first TNF-α inhibitor. These studies were selected and weighted rates were evaluated as described above and in Table 3. A total of 12 publications [16,27-29,33-38,50,51,53] provided these rates for one or more of the following groups according to reason for discontinuing a first TNF-α inhibitor: (1) lack of efficacy (patients who never achieved a response, also referred to as primary failures), (2) loss of efficacy (patients who experienced a response but lost this response over time, also referred to as secondary failures) and (3) intolerance and/or adverse events (also referred to as safety failures).

Five publications which were initially identified for potential inclusion in these analyses had to be excluded because of problems in the way this information was reported. Two studies [49,61] were excluded because only change in continuous outcomes (HAQ and DAS28) was reported. One study [58] which reported the effects of adalimumab treatment among TNF-α inhibitor inadequate responders was excluded because the length of the period leading up to assessment of response varied between 1 and 19 months, making it difficult to interpret the published rate. One study [52] was excluded because it reported ACR response rates according to whether the reason for discontinuation was related to efficacy, which did not fit with the classification defined above. A fifth study [47] was excluded because its eligibility criteria limited the patient sample to those who responded to treatment with infliximab and switched to etanercept as a result of adverse events. We find that this particular group of patients is likely not comparable to those included in the remaining studies, since for other studies patients were classified as safety failures because this was the primary reason for discontinuation, regardless of whether they had experienced an effective response to the first TNF-α inhibitor.

Figure 3 presents the weighted ACR, DAS28 and EULAR rates of response for a second TNF-α inhibitor by reason for discontinuation of an initial TNF-α inhibitor. It should be noted that DAS28-based remission (DAS28 <2.6) rates were reported only for safety failures, making it impossible to compare the three groups based on this response criterion. Response rates for primary versus secondary failures were not consistently ordered across the six response criteria shown in Figure 3. On the basis of ACR response rates, secondary failures appear to have a greater likelihood of responding to a second TNF-α inhibitor. Contrary to this finding, rates of EULAR moderate response suggested that a greater proportion of primary failures would respond to a second TNF-α inhibitor compared to secondary failures. The two remaining response criteria (EULAR good and DAS28 ≤3.2) are generally too close to suggest a clear difference between these two groups.

Two key differences may help explain the discrepancies in these results. First, the study follow-up (or time to assessment of response) tended to be somewhat longer in the studies in which rates of DAS-based remission and rates of EULAR moderate response were derived than in studies used to derive ACR and good EULAR response rates. Second, these estimates were often based on a few studies with total sample sizes that ranged between 98 and 250 patients. In contrast, ACR response rates and EULAR good response rates were each estimated on the basis of four or more studies with total sample sizes that ranged between 251 and 609 patients, making the ACR and EULAR good response estimates somewhat more robust. Nearly 50% and 60% of primary and secondary failures, respectively, were estimated to achieve an ACR20 response. Overall, ACR response rates were approximately 20% to 30% higher for secondary failures when compared to those of primary failures.

In contrast to the results obtained for primary and secondary failures, response rates to a second TNF-α
inhibitor were consistently higher among patients who switched for safety-related reasons. More than 60% of safety failures were estimated to reach an ACR20 response, and about one-half (51%) were estimated to experience a EULAR moderate response; approximately one-third of these patients achieved an ACR50 response and low disease activity (DAS28 ≤ 3.2).

Efficacy estimates stratified by length of follow-up
Since the ideal period for determining whether a response to treatment has occurred remains controversial [62] and varied considerably across the selected studies, we examined how efficacy varied by length of follow-up or time of efficacy assessment. Differences in ACR20 response rates for the second versus third biologic drug used were similar for treatment durations of 3 to 4 months and durations of 6 months or more (about 10% in both cases).

Discussion
In the current study, the association of response to subsequent biologic treatment with number of previous TNF-α inhibitor treatments was evaluated on the basis of data reported in peer-reviewed publications. After combining these data, the results indicated that an association does in fact appear to exist and that response is likely to decline with increasing number of previous TNF-α inhibitors. ACR20 means a 20% improvement in tender or swollen joint counts as well as 20% improvement in at least three of the following five criteria: patient assessment, physician assessment, erythrocyte sedimentation rate, pain scale and functional questionnaire. The ACR50 and ACR70 categories adhere to the same criteria, but for 50% and 70% improvement, respectively.

### Table 3 Information used to evaluate the proportion of patients achieving a response to a second biologic DMARD according to common criteria used in RA studies by reason for discontinuation of a first TNF-α inhibitor*

| Measure      | Reason for discontinuation | Total number of patients | Estimated response rate, % | Biologics used to derive rate | Treatment duration range, months | Mean RA duration range, yr | Reference sources |
|--------------|----------------------------|--------------------------|-----------------------------|-------------------------------|---------------------------------|--------------------------|-------------------|
| ACR20        | Intolerance                | 337                      | 62.5                        | ADA and TNF$_i$               | 3                               | 12                      | [17,36,51,53]     |
|              | Lack of efficacy           | 251                      | 48.4                        | ADA and ETN                   | 3 to 4                          | 9 to 12                  | [34,36,37,53]     |
|              | Loss of efficacy           | 609                      | 58.0                        | ADA and ETN                   | 3 to 6                          | 9 to 12                  | [30,34,36,37,53]  |
| ACR50        | Intolerance                | 337                      | 35.7                        | ADA and ETN                   | 3                               | 12                      | [17,36,51,53]     |
|              | Lack of efficacy           | 251                      | 23.6                        | ADA and ETN                   | 3 to 4                          | 9 to 12                  | [34,36,37,53]     |
|              | Loss of efficacy           | 537                      | 29.6                        | ADA and ETN                   | 3 to 4                          | 9 to 12                  | [34,36,37,53]     |
| ACR70        | Intolerance                | 337                      | 13.4                        | ADA and TNF$_i$               | 3                               | 12                      | [17,36,51,53]     |
|              | Lack of efficacy           | 251                      | 9.0                         | ADA and ETN                   | 3 to 4                          | 9 to 12                  | [34,36,37,53]     |
|              | Loss of efficacy           | 537                      | 12.0                        | ADA and ETN                   | 3 to 4                          | 9 to 12                  | [34,36,37,53]     |
| DAS28 <2.6   | Intolerance                | 443                      | 15.2                        | ABA and TNF$_i$               | 3 to 6                          | NR                      | [17,29]           |
| DAS28 <3.2   | Intolerance                | 211                      | 30.4                        | TNF$_i$                       | 3 to 6                          | 6                       | [17,35]           |
|              | Lack of efficacy           | 98                       | 13.0                        | TNF$_i$                       | 3 to 6                          | 6                       | [35]              |
|              | Loss of efficacy           | 150                      | 12.0                        | TNF$_i$                       | 3 to 6                          | 6                       | [35]              |
| EULAR moderate | Intolerance              | 250                      | 38.8                        | TNF$_i$                       | 3                               | 9                      | [38,45,50]        |
|              | Lack of efficacy           | 98                       | 37.0                        | TNF$_i$                       | 3 to 6                          | 6                       | [35]              |
|              | Loss of efficacy           | 150                      | 18.0                        | TNF$_i$                       | 3 to 6                          | 6                       | [35]              |
| EULAR good   | Intolerance                | 718                      | 21.3                        | ADA and TNF$_i$               | 3 to 12                         | 6 to 12                  | [17,35,36,38,50,53] |
|              | Lack of efficacy           | 320                      | 15.2                        | ADA, ETN and TNF$_i$          | 3 to 6                          | 6 to 12                  | [35-37]           |
|              | Loss of efficacy           | 515                      | 16.9                        | ADA, ETN and TNF$_i$          | 3 to 6                          | 6 to 12                  | [35-37]           |
| EULAR moderate/ good | Intolerance        | 467                      | 69.5                        | ADA and TNF$_i$               | 3 to 6                          | 6 to 12                  | [17,35,36,45,53]  |
|              | Lack of efficacy           | 349                      | 63.2                        | ADA, ETN and TNF$_i$          | 3 to 6                          | 6 to 12                  | [34-37,53]        |
|              | Loss of efficacy           | 687                      | 60.7                        | ADA, ETN and TNF$_i$          | 3 to 6                          | 6 to 12                  | [34-37,53]        |

*DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; ACR, American College of Rheumatology; DAS28, Disease Activity Score 28 joint count; EULAR, European League Against Rheumatism; ABA, abatacept; ADA, adalimumab; ETN, etanercept; TNF$_i$, $i$th TNF-α inhibitor; ABA, abatacept; ADA, adalimumab; TNF$_i$, $i$th TNF-α inhibitor. ACR20 means a 20% improvement in tender or swollen joint counts as well as 20% improvement in at least three of the following five criteria: patient assessment, physician assessment, erythrocyte sedimentation rate, pain scale and functional questionnaire. The ACR50 and ACR70 categories adhere to the same criteria, but for 50% and 70% improvement, respectively.
was also maintained across a number of important RA response measures, which further contributes to the validity of the findings. Furthermore, the ACR response rates derived in the current study for patients with no prior exposure to biologic drugs are in line with those reported in previous studies that examined 6-month outcomes from RCTs using patients previously not exposed to biologic DMARDs [10].

One limitation of the current study is that the degree of heterogeneity across studies was not summarized quantitatively. Nevertheless, it must be clear from our exposition regarding the difficulties in combining results across studies that a large degree of variation in study design and patient characteristics was present. In addition, the results that were central to our research question were frequently incidental to the primary objectives of the studies that were reviewed, which meant that information specific to groups of patients differing in the number of prior TNF-α inhibitors used was often lacking. Consequently, no formal statistical inference was undertaken, which is another limitation of the study.

Despite having found several results supporting a trend of lower efficacy rates with increased number of previous TNF-α inhibitors used, we believe that more research into this topic is needed before a conclusion

![Figure 3 Percentage of patients responding to a second TNF-α inhibitor by reason for discontinuation of first.](http://arthritis-research.com/content/13/1/R25)

Figure 3 Percentage of patients responding to a second TNF-α inhibitor by reason for discontinuation of first. Bar graph showing the percentage of patients achieving a response to a second tumor necrosis factor (TNF)-α inhibitor according to criteria commonly used in rheumatoid arthritis by reason of discontinuation of the initial TNF-α inhibitor. ACR, American College of Rheumatology (see Figure 1 legend for description of ACR20, ACR50 and ACR 70 criteria); DAS28, Disease Activity Score 28 joint count; EULAR, European League Against Rheumatism.
can be reached. In particular, the safety of biologic treatment specifically in patients with an inadequate response to TNF-α inhibitors must also be addressed before the strategy of switching can be fully evaluated vis-à-vis alternative therapies.

One potential key factor in predicting response after a switch to an alternative biologic drug is the reason for discontinuation of the prior drug. The current study examined this aspect of RA treatment within the scope of the available data on this topic, which did not enable a comparison of patients who switched to a second biologic DMARD that was not within the TNF-α inhibitor class. Although several studies did report reasons for discontinuation of prior TNF-α inhibitor treatment, only a few reported response rates for groups of patients who differed in the reason for discontinuation. Our results indicate that patients who discontinue treatment as a result of adverse events are more likely to achieve a clinical response to a second TNF-α inhibitor than are patients who discontinue the first TNF-α inhibitor for efficacy-related reasons. Higher response rates [30] and greater declines in DAS28 values [49] among safety failures have been reported in other studies. Nevertheless, some caution should be taken when interpreting these findings, since the assessment of these rates could be sensitive to the length of follow-up in a particular study. Two large studies based on registry cohorts [16,45] reported that the reason for discontinuation of a first TNF-α inhibitor was likely to explain the reason for discontinuation of a second TNF-α inhibitor, while the findings from another large registry cohort could not confirm this relationship [50]. Further, response rates in a RCT of the newer biologic agent tocilizumab [52] were nearly identical for patients who discontinued treatment because of inefficacy or for unrelated reasons. Overall, we observed consistently higher response rates among safety failures than among primary and secondary efficacy failures. Data obtained over longer follow-up periods, however, are needed to confirm or disprove the findings of the current study.

The exact form of the relationship between response to treatment and number of failed TNF-α inhibitors is likely to play an increasingly important role in defining treatment strategies for RA patients who have had an inadequate response to treatment with TNF-α inhibitors. Given the high cost of biologic agents and evolving knowledge of their safety profiles, there is a growing need to compare and evaluate the relative benefit of strategies involving alternative sequences of therapies. The recent availability of a number of newer biologic drugs with different mechanisms of action makes this need even more salient. Establishing patterns of response along the treatment pathway is a key element of these evaluations, as is the identification of subgroups of patients who may differ in these response patterns. In addition to providing insight into the existence of an association between treatment response and increasing number of failed TNF-α inhibitors, the current study has also offered an overview of the multiple difficulties that are faced when synthesizing evidence pertaining to this question. Differences in reporting, study design and the overall availability of data have made this task a difficult one, which is apparent from the results presented herein.

Given that a substantial proportion of patients will fail an initial biologic treatment, establishing when and how to initiate treatment with these agents is just as important as establishing the relative value of long-term treatment strategies. In many instances, these long-term strategies involve a sequence of treatments, so the question arises at each step which therapy to use as a replacement when a particular therapy must be stopped because of inefficacy or intolerance. Multiple studies have addressed this question in a number of different ways. To date, the large majority consist of observational studies. Some of the results of earlier observational studies were based on small samples and relatively short follow-up periods [29,44,46,51], but more recently the accumulation of data from several registries of RA patients [61] treated with biologic drugs has provided larger sample sizes and longer duration of follow-up. In addition, while the older biologic DMARDs were compared primarily with nonbiologic DMARDs, RCTs of newer biologic drugs have used samples of patients with an inadequate response to one or more biologic DMARDs, primarily TNF-α inhibitors [63]. Several reviews [64-68] have attempted to summarize data from these publications. A recent meta-analysis [69] presented a quantitative evaluation of the effectiveness of switching treatments, specifically between TNF-α inhibitors. These results suggested that the probability of achieving a clinical response declines after the first TNF-α inhibitor, a trend that was observed in our study as well, even when other biologic DMARDs were considered. Although data were limited, we found that the magnitude of this decline may depend on the type of biologic drug administered. For example, DAS28-based results suggested that when the third biologic is a TNF-α inhibitor, response rates may be lower than those of an alternative biologic. Although readers are cautioned to consider the limitations of the available data and the preliminary nature of the findings, our study strengthens and extends the findings presented in the meta-analysis of Lloyd et al. [69].

Establishing the existence and magnitude of a relationship between responses to biologic drug treatment and the number of previously failed TNF-α inhibitors has a number of important implications. From a clinical
practice perspective, understanding such a relationship can help clinicians to decide on a treatment to use from amongst an increasing number of alternative strategies. From a research perspective, the current investigation may help inform future studies that involve the treatment of RA patients over the course of their lifetimes, such as economic assessments of RA therapies based on treatment sequence models. One of the key objectives of this work was to provide a more quantitative analysis of the data reported in studies of patients refractory to TNF-α inhibitors, something that was lacking in the current literature. In addition, the current study has exposed some of the difficulties associated with combining results across studies with different designs, patient populations and reported outcome measures. Exposing these limitations may improve the design of future research and foster greater harmonization of RA clinical studies that aim to investigate the effects of sequential biologic drug therapies in RA.

Conclusions

For patients with prior exposure to TNF-α inhibitors, the likelihood of a response to subsequent treatment with biologic agents declines with an increasing number of previous TNF-α inhibitor treatments.

Additional material

Additional file 1: Table S1. Characteristics and main findings of studies included in the analyses. Description: Microsoft Word table containing the following information for each of the 28 studies included in the analyses: study publication(s); study design, anti-tumor necrosis factor (anti-TNF) groups (anti-TNF naïve, first-, second- or third-time switchers and the biologics involved); disease duration; mean age, baseline DAS28; duration of follow-up (months); and key study findings.

Abbreviations

ABPA: abatacept; ACR: American College of Rheumatology; ADA: adalimumab; ANA: antinuclear antibody; CRP: C-reactive protein; DAS28: Disease Activity Score 28 joint count; DMARD: disease-modifying antirheumatic drug; ESR: erythrocyte sedimentation rate; ETN: etanercept; EULAR: European League Against Rheumatism; GLM: golimumab; HAQ: Health Assessment Questionnaire; IFX: infliximab; LEL: leflunomide; MTX: methotrexate; NICE: National Institute for Clinical Excellence; RCT: randomized controlled trial; RTX: rituximab; TCCZ: tocilizumab; TNF: tumor necrosis factor; VAS: Visual Analog Scale.

Acknowledgements

This study was sponsored by Pfizer. RRB and GVW are employees of Pfizer Inc. who were paid consultants to Pfizer in connection with the development of this manuscript. GW, TK, JB and SHZ are employees of Pfizer Inc. RRB, MY and MK are paid consultants to Pfizer Inc.

Author details

1QualityMetric Inc, Outcomes Insight Consulting Division, 24 Albion Road, Lincoln, RI 02865, USA. 2Pfizer Clinical Development and Medical Affairs, 50 Pequot Avenue, 6025-B3206, New London, CT 06320, USA. 3Pfizer Clinical Development and Medical Affairs, 235 East 42nd Street, New York, NY 10017, USA.

Authors’ contributions

RRB and GVW performed the literature search and data analysis and wrote and edited the manuscript. TK, JB and SHZ assisted with the editing of the manuscript, the subject matter content and the conclusions. MY and MK assisted with the development of the manuscript outline, the conceptualization of the study and data interpretation. All authors were involved in discussion of the findings as well as in the drafting and final approval of the manuscript.

Competing interests

GW, TK, JB and SHZ are employees of Pfizer Inc, the sponsor of this study. RRB, MY and MK have served as consultants for Pfizer.

Received: 23 August 2010 Revised: 30 December 2010 Accepted: 16 February 2011 Published: 16 February 2011

References

1. van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blauw AA, Kruize AA, Hofman DM, Bruijnzeel-Koomen CA, Alabrandi E, Ter Borg EJ, Haenen HC, van Roon-Cortep S, Cersch Y, Bijlma JW. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis 2005; 64:466-472.
2. Nell VP, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43:906-914.
3. Lard LR, Visser H, Speyer I, vander Horst-Bruimena IE, Zwinderena AH, Breedveld FC, Haze JMW. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Ann J Med 2001; 111:446-451.
4. Saag KG, Teng G, Patkar NM, Anjumty J, Finney C, Curtis JR, Paulus HE, Mudano A, Pina M, Elinson-Melton M, O’Lemarr R, Allison JJ, Suarez-Almazor M, Bridge SL, Jr, Chatham WW, Hochberg M, MacLean C, McKus T, Moreland LW, O’Dell J, Turkewicz AM, Forst DE, American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 763-784.
5. Lopez-Orilo MA, Kallan MA, Ortiz Z, Skidmore B, Suarez-Almazor ME. Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: a systematic review. Arthritis Rheum 2008; 59: 1625-1635.
6. Kamali KM, Madhavan SS, Hornby JA, Miller LA, Kavokaian J, Scott V. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists. Joint Bone Spine 2006; 73: 718-724.
7. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Orilo MA, Tianjorng Ghomme L, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochranetools. Cochrane Database Syst Rev 2009; 4:CD007848.
8. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, Tugwell P, Weinblatt M, Williams HJ, Wolfe F, Kieskes S, American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 227-235.
9. Herland ML, Christensen LJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollevang G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Ostergaard M, All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62: 22-32.
10. Nixon R, Bancrback N, Brennan A. The efficacy of inhibiting tumour necrosis factor α and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford) 2007; 46: 1140-1147.
11. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Orilo MA, Ghomme ET, Tugwell P. A network meta-analysis of...
randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009, 181:787-796.

12. Donahue KE, Gertlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, Hansen RA, Morgan LC, Loht RN: Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008, 148:124-134.

13. Navarro F, Gomez-Reino JJ, Marsal S, Navarro F, Gomez-Reino JJ, Marsal S: Clinical outcomes of patients with rheumatoid arthritis after switching from etanercept to adalimumab in patients with rheumatoid arthritis. J Rheumatol 2007, 34:1184-1191.

14. Brocq O, Albert C, Roux C, Gerard D, Breuil V, Ziegler LE: Outcome of discontinuing TNF-α antagonists in rheumatoid arthritis patients with rheumatoid arthritis. J Rheumatol 2004, 31:2536-2539.

15. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ: Outcome after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007, 56:13-20.

16. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, Weisman M, Rendas-Baum et al: Effectiveness of a switch to a second anti-TNF-α antagonist therapy in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003, 62:1195-1198.

17. Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B: Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) 2005, 44:1026-1031.

18. Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M: Abatacept for rheumatoid arthritis refractory to anti-tumour necrosis factor α inhibition. N Engl J Med 2005, 353:1114-1123.

19. Cohen MC, Schiff M, Luggen M, Murrey K, Arndt D, Hepler S, Reus V, Raghav R, Saha A, Shulman LE: The efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor α therapy were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009, 68:1708-1714.

20. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanzache A, Alecock E, Lee J, Kremer J: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor α biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008, 67:1516-1523.

21. Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B: Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) 2005, 44:1026-1031.

22. Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M: Abatacept for rheumatoid arthritis refractory to anti-tumour necrosis factor α inhibition. N Engl J Med 2005, 353:1114-1123.

23. Cohen MC, Schiff M, Luggen M, Murrey K, Arndt D, Hepler S, Reus V, Raghav R, Saha A, Shulman LE: The efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor α therapy were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009, 68:1708-1714.

24. Schiødt M, Pritchard C, Hufstetter JE, Rodriguez-Valverde V, Durez P, Zhou X, Li T, Bahrt K, Kelly S, Le Bars M, Genovese MC: The 6-month safety and
etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004, 31:1098-1102.

45. Hjermstad E, Østergaard M, Pedersen J, Tarp U, Andersen LS, Bing J, Peen E, Lindgaard HM, Ringdal VS, Radgaard A, Skat J, Hansen A, Mogensen HH, Unkerskov J, Hetland ML: Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor α inhibitor? Ann Rheum Dis 2007, 66:1184-1189.

46. Hyrich K, Lunt M, Dixon WG, Watson KD, Symmons DPM: Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) 2008, 47:1000-1005.

47. Iannone F, Trotta F, Montecucco C, Gacelli R, Galeazzi M, Matucci-Cerinic M, Feni C, Cutillo M, Maria Barbbara L, Tirolio G, Ferraccioli G, Valentini G, Lapadula G, GISEA (Gruppo Italiano per lo Studio delle Early Arthritides): Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis 2007, 66:249-252.

48. Keystone E, Emery P, Peterfy CG, Tack PP, Cohen S, Genovese MC, Dougados M, Burmester GR, Greenwald M, Kien TK, Williams S, Hagerty D, Cravets MW, Shaw T: Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009, 68:216-221.

49. Lopes K, Petrakis R, Kauhanen H, Leirisalo-Repo M: Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. Clin Rheumatol 2008, 27:927-932.

50. Navarro-Sarabia F, Ruiz-Montesinos D, Hernandez B, Navarro-Compan Y, Marsal S, Barcelo M, Perez-Pampin E, Gomez-Reino J: DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists. Biomed J Musculoskelet Disord 2009, 10:91.

51. Nikas SN, Voulgari PV, Alamanos Y, Papadopoulos CG, Venetanopoulos AJ, Georgiadis AN, Drosos AA: Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 2006, 65:257-260.

52. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MJ, GO-AFTER study investigators: Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009, 374:210-217.

53. van der Bij AE, Breedveld FC, Antoni CE, Kalden JR, Kay S, Burmester GR, Beckmann C, Unnebrink K, Kupper H: An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 2008, 27:1021-1028.

54. van Gestel AM, Haagsma CJ, van Riel PL: Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998, 41:1845-1850.

55. Fransen J, Cremer MC, van Riel PL: Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004, 43:1252-1255.

56. van Gestel A, van Riel P: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis: comment on the article by Felson et al. Arthritis Rheum 1996, 39:533-537.

57. Matsui T, Kugoh Y, Kaneko A, Nishino J, Eto Y, Chiba N, Yasuda M, Saito K, Shimada K, Tohma S: Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 2007, 66:1221-1226.

58. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Alehata D, van Riel PL: Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009, 68:954-960.

59. Zink A, Strangfeld A, Schneider M, Herzer P, Hesse R, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J: Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006, 54:3399-3407.

60. Zink A, Askling J, Dixon WG, Klareskog L, Silman AJ, Symmons DP: European biologicals registers: methodology, selected results and perspectives. Ann Rheum Dis 2009, 68:1240-1246.